Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,088
  • Shares Outstanding, K 20,412
  • Annual Sales, $ 84,510 K
  • Annual Income, $ -60,640 K
  • 60-Month Beta 1.74
  • Price/Sales 0.41
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FBIO with:

Options Overview Details

View History
  • Implied Volatility 146.64% ( +65.39%)
  • Historical Volatility 51.66%
  • IV Percentile 29%
  • IV Rank 8.89%
  • IV High 1,346.66% on 08/17/23
  • IV Low 29.60% on 10/11/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 19
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 1,474
  • Open Int (30-Day) 1,464

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.32
  • Number of Estimates 2
  • High Estimate -0.88
  • Low Estimate -1.75
  • Prior Year -3.60
  • Growth Rate Est. (year over year) +63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +10.00%
on 06/27/24
2.0500 -14.15%
on 06/17/24
-0.1300 (-6.88%)
since 06/03/24
3-Month
1.6000 +10.00%
on 06/27/24
2.0697 -14.96%
on 05/21/24
-0.1600 (-8.33%)
since 04/03/24
52-Week
1.2400 +41.94%
on 11/10/23
10.3500 -83.00%
on 07/24/23
-6.7480 (-79.31%)
since 07/03/23

Most Recent Stories

More News
Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech: Q1 Earnings Snapshot

FBIO : 1.7600 (+5.39%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.7600 (+5.39%)
Fortress Biotech: Q2 Earnings Snapshot

Fortress Biotech: Q2 Earnings Snapshot

FBIO : 1.7600 (+5.39%)
Fortress Biotech: Q1 Earnings Snapshot

Fortress Biotech: Q1 Earnings Snapshot

FBIO : 1.7600 (+5.39%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 1.7600 (+5.39%)
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...

FBIO : 1.7600 (+5.39%)
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...

DERM : 5.15 (-1.72%)
FBIO : 1.7600 (+5.39%)
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics ...

FBIO : 1.7600 (+5.39%)
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...

FBIO : 1.7600 (+5.39%)
DERM : 5.15 (-1.72%)
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...

FBIO : 1.7600 (+5.39%)
DERM : 5.15 (-1.72%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 2.0300
2nd Resistance Point 1.9400
1st Resistance Point 1.8500
Last Price 1.7600
1st Support Level 1.6700
2nd Support Level 1.5800
3rd Support Level 1.4900

See More

52-Week High 10.3500
Fibonacci 61.8% 6.8700
Fibonacci 50% 5.7950
Fibonacci 38.2% 4.7200
Last Price 1.7600
52-Week Low 1.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar